Cargando…

Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting

Background and Purpose: Patients undergoing carotid artery stenting (CAS) who show low responsiveness to clopidogrel may have a higher risk of peri-procedural embolic events. This study aimed to compare the effectiveness and safety of clopidogrel and ticlopidine plus Ginkgo biloba in clopidogrel-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jong-Won, Kim, Suk Jae, Hwang, Jaechun, Lee, Mi Ji, Lee, Jun, Lee, Kyung-Yul, Park, Man-Seok, Sung, Sang Min, Kim, Keon Ha, Jeon, Pyoung, Bang, Oh Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363652/
https://www.ncbi.nlm.nih.gov/pubmed/30761076
http://dx.doi.org/10.3389/fneur.2019.00044
_version_ 1783393137753849856
author Chung, Jong-Won
Kim, Suk Jae
Hwang, Jaechun
Lee, Mi Ji
Lee, Jun
Lee, Kyung-Yul
Park, Man-Seok
Sung, Sang Min
Kim, Keon Ha
Jeon, Pyoung
Bang, Oh Young
author_facet Chung, Jong-Won
Kim, Suk Jae
Hwang, Jaechun
Lee, Mi Ji
Lee, Jun
Lee, Kyung-Yul
Park, Man-Seok
Sung, Sang Min
Kim, Keon Ha
Jeon, Pyoung
Bang, Oh Young
author_sort Chung, Jong-Won
collection PubMed
description Background and Purpose: Patients undergoing carotid artery stenting (CAS) who show low responsiveness to clopidogrel may have a higher risk of peri-procedural embolic events. This study aimed to compare the effectiveness and safety of clopidogrel and ticlopidine plus Ginkgo biloba in clopidogrel-resistant patients undergoing CAS. Methods: In this multi-center, randomized, controlled trial, we used platelet reactivity test to select patients undergoing CAS who showed clopidogrel resistance, and compared treatments using clopidogrel and ticlopidine plus ginkgo. The primary outcome was the incidence of new ischemic lesion in the ipsilateral hemisphere of CAS. Detection of microembolic signal on transcranial Doppler was the secondary outcome. The clinical outcomes were also monitored. Results: This trial was discontinued after 42 patients were randomized after preplanned interim sample size re-estimation indicated an impractical sample size. The primary endpoint occurred in 12/22 patients (54.5%) in the clopidogrel group and 13/20 patients (65.0%) in the ticlopidine–ginkgo group (P = 0.610). No significant differences in the presence of microembolic signal (15.0 vs. 11.8%, P = 0.580), clinical outcomes (ischemic stroke or transient ischemic attack, 0.0 vs. 5.5%; acute myocardial infarction 0.0 vs. 0.0%; all-cause death, 4.5 vs. 0.0%), or incidence of adverse events were found in the two groups. In terms of resistance to clopidogrel, treatment with ticlopidine–ginkgo significantly increased the P2Y12 Reaction Units (difference, 0.0 [−0.3–3.0] vs. 21.0 [6.0–35.0], P < 0.001). Conclusions: In patients who showed clopidogrel resistance, ticlopidine–ginkgo treatment was safe and increased P2Y12 Reaction Units; however, compared to clopidogrel, it failed to improve surrogate and clinical endpoints in patients undergoing CAS. This multimodal biomarker-based clinical trial is feasible in neurointerventional research. Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT02133989.
format Online
Article
Text
id pubmed-6363652
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63636522019-02-13 Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting Chung, Jong-Won Kim, Suk Jae Hwang, Jaechun Lee, Mi Ji Lee, Jun Lee, Kyung-Yul Park, Man-Seok Sung, Sang Min Kim, Keon Ha Jeon, Pyoung Bang, Oh Young Front Neurol Neurology Background and Purpose: Patients undergoing carotid artery stenting (CAS) who show low responsiveness to clopidogrel may have a higher risk of peri-procedural embolic events. This study aimed to compare the effectiveness and safety of clopidogrel and ticlopidine plus Ginkgo biloba in clopidogrel-resistant patients undergoing CAS. Methods: In this multi-center, randomized, controlled trial, we used platelet reactivity test to select patients undergoing CAS who showed clopidogrel resistance, and compared treatments using clopidogrel and ticlopidine plus ginkgo. The primary outcome was the incidence of new ischemic lesion in the ipsilateral hemisphere of CAS. Detection of microembolic signal on transcranial Doppler was the secondary outcome. The clinical outcomes were also monitored. Results: This trial was discontinued after 42 patients were randomized after preplanned interim sample size re-estimation indicated an impractical sample size. The primary endpoint occurred in 12/22 patients (54.5%) in the clopidogrel group and 13/20 patients (65.0%) in the ticlopidine–ginkgo group (P = 0.610). No significant differences in the presence of microembolic signal (15.0 vs. 11.8%, P = 0.580), clinical outcomes (ischemic stroke or transient ischemic attack, 0.0 vs. 5.5%; acute myocardial infarction 0.0 vs. 0.0%; all-cause death, 4.5 vs. 0.0%), or incidence of adverse events were found in the two groups. In terms of resistance to clopidogrel, treatment with ticlopidine–ginkgo significantly increased the P2Y12 Reaction Units (difference, 0.0 [−0.3–3.0] vs. 21.0 [6.0–35.0], P < 0.001). Conclusions: In patients who showed clopidogrel resistance, ticlopidine–ginkgo treatment was safe and increased P2Y12 Reaction Units; however, compared to clopidogrel, it failed to improve surrogate and clinical endpoints in patients undergoing CAS. This multimodal biomarker-based clinical trial is feasible in neurointerventional research. Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT02133989. Frontiers Media S.A. 2019-01-30 /pmc/articles/PMC6363652/ /pubmed/30761076 http://dx.doi.org/10.3389/fneur.2019.00044 Text en Copyright © 2019 Chung, Kim, Hwang, Lee, Lee, Lee, Park, Sung, Kim, Jeon and Bang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Chung, Jong-Won
Kim, Suk Jae
Hwang, Jaechun
Lee, Mi Ji
Lee, Jun
Lee, Kyung-Yul
Park, Man-Seok
Sung, Sang Min
Kim, Keon Ha
Jeon, Pyoung
Bang, Oh Young
Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title_full Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title_fullStr Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title_full_unstemmed Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title_short Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting
title_sort comparison of clopidogrel and ticlopidine/ginkgo biloba in patients with clopidogrel resistance and carotid stenting
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363652/
https://www.ncbi.nlm.nih.gov/pubmed/30761076
http://dx.doi.org/10.3389/fneur.2019.00044
work_keys_str_mv AT chungjongwon comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT kimsukjae comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT hwangjaechun comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT leemiji comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT leejun comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT leekyungyul comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT parkmanseok comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT sungsangmin comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT kimkeonha comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT jeonpyoung comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting
AT bangohyoung comparisonofclopidogrelandticlopidineginkgobilobainpatientswithclopidogrelresistanceandcarotidstenting